DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Benicar (Olmesartan Medoxomil) - Published Studies

 
 



Benicar Related Published Studies

Well-designed clinical trials related to Benicar (Olmesartan)

Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. [2014]

Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. [2014]

Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. [2013]

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. [2011.06]

Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. [2011.06]

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. [2011.04]

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. [2011.03]

The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. [2011.02]

Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. [2011.01.22]

A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. [2011.01]

Olmesartan/amlodipine: a review of its use in the management of hypertension. [2011]

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. [2011]

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. [2011]

Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. [2010.12]

Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. [2010.11]

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. [2010.11]

The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. [2010.08]

A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. [2010.06]

Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. [2010.03]

Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. [2010]

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. [2010]

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. [2009.12]

Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. [2009.12]

Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. [2009.11]

Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. [2009.10]

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. [2009.09]

Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. [2009.08.01]

Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. [2009.08]

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). [2009.07]

Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. [2009.02]

Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. [2009.02]

Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. [2009.01]

Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. [2009]

Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. [2009]

Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. [2009]

Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods. [2008.12.20]

Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. [2008.07]

Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. [2008]

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. [2007.12]

Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. [2007.03]

Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. [2007]

Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. [2006.09]

Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. [2006.09]

Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. [2006.07]

Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. [2006.06]

Prevention of migraine with olmesartan in patients with hypertension/prehypertension. [2006.03]

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. [2006.02]

A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. [2006]

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. [2006]

Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. [2006]

Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. [2005.01]

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. [2005]

Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. [2004.08]

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. [2004.03]

Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. [2004.03]

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. [2003.06]

Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. [2003]

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? [2002.11]

Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. [2002.09]

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. [2001.09]

Well-designed clinical trials possibly related to Benicar (Olmesartan)

Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. [2015]

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). [2011]

Estimating Antihypertensive Effects of Combination Therapy in an Observational Study Using Marginal Structural Models. [2009.10.13]

Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models. [2009.10]

Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs: A Systematic Review and Meta-Analysis. [2009]

Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. [2007.08]

Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. [2007.01]

Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. [2006.04]

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. [2006.03]

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. [2006.01.05]

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. [2005.11]

Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. [2005.04]

Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. [2005.04]

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. [2004.08.31]

The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. [2002.10]

Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. [2001.05]

Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. [1997.12]

Other research related to Benicar (Olmesartan)

Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. [2014]

[The effects of olmesartan on ambulatory blood pressures and blood pressure variability in patients with mild to moderate essential hypertension]. [Article in Chinese] [2014]

Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. [2014]

Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. [2014]

Olmesartan in the treatment of hypertension in elderly patients: a review of the primary evidence. [2013]

Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. [2013]

Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. [2013]

Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. [2013]

Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design. [2013]

Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration. [2013]

Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. [2013]

Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris. [2013]

Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study. [2013]

Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. [2013]

The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. [2013]

Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. [2013]

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. [2012]

Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. [2012]

Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients. [2012]

Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. [2012]

24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. [2011.12]

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. [2011.11.25]

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. [2011.09]

Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. [2011.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017